2022: Volume 5, Issue 5
Short Communication P.1-2
An expressive note on biomarkers to create pharmacotherapy improvement and mutation drug resistance
Author(s): Belanger Lucas*
Mini Review P.1-2
Scientific progresses and hones of chemotherapy resistance and drug technology in tongue cancers.
Author(s): Thomas Mulder*
Commentary P.1-2
Clinical data management and pharmacological considerations in intense lymphoblastic leukaemia patients.
Author(s): Williams James*
Perspective P.1-2
Clinical trials and cognitive perspectives related to pharmacological options for the treatment of acute myeloid leukaemia.
Author(s): Paul Schmidt*
Opinion Article P.1-2
Pharmacovigilance and adverse drug reactions medicine-based drug treatment individualization in oncology
Author(s): Bernard Arthur*